Comparative in vitro quality evaluation of Metronidazole tablets
- VernacularTitle:Метронидазол 500 мг шахмал эмийн in-vitro орчинд хийсэн чанарын судалгаа
- Author:
Azjargal G
1
;
Tungalag Ts
1
;
Otgonchimeg T
1
;
Gereltuya D
1
Author Information
1. Mongolian University of Pharmaceutical Sciences
- Publication Type:Journal Article
- Keywords:
Metronidazole;
in vitro comparative study;
disintegration time;
dissolution profile
- From:
Mongolian Pharmacy and Pharmacology
2024;24(1):57-62
- CountryMongolia
- Language:Mongolian
-
Abstract:
Introduction: Quality of pharmaceutical products is very important because drugs must be marketed as safe
and therapeutically active formulations whose performance is consistent and predictable. The evaluation of
the physical characteristics of the pharmaceutical products can ensure their quality as well as bioavailability
and impart optimum therapeutic activity. Metronidazole was chosen for this comparative study because this
drug is widely used worldwide in the treatment of amoebiasis and other microbial diseases.
Method: The quality control parameters of five different brands of metronidazole 500 mg tablets were
determined weight variation, friability, hardness, and disintegration, dissolution and assay tests. All the tablets
were evaluated for conformity with British Pharmacopoeia (BP) and Mongolian Pharmacopoeia-National
Formulary (MP-NF) standards.
Results: Among five brands of tablets Brand М3 had lower mean weight variation of 0.8% and Brand М1
had highest mean weight variation of 3.42%. For friability test Brand М2 had the lowest mean friability (0.57)
and Brand М1 had highest mean friability (1.51). The disintegration time for five brands of ciprofloxacin tablet
obtained were in the subsequent order: Brand М1 (2.82 min) < Brand М3 (8.8 min) < Brand М4 (12.32 min)
< Brand М5 (13.82 min) < Brand М1 (39.22 min).
Conclusion: The present study revealed that all of the leading brands (M1, M2, M3, M4, M5) of this tablet
met the quality control parameters as per pharmacopoeial specifications.
- Full text:2025051101492284835MPPJ-2024-24(1)-57-62.pdf
